Cover Image
市場調查報告書

免疫查核點抑制劑:臨床實驗追蹤分析

Immune Checkpoint Inhibitors: Clinical Trial Tracker

出版商 ROOTS ANALYSIS 商品編碼 364586
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
免疫查核點抑制劑:臨床實驗追蹤分析 Immune Checkpoint Inhibitors: Clinical Trial Tracker
出版日期: 2016年07月21日 內容資訊: 英文
簡介

癌症治療到目前為止,分成外科手術、放射治療、化療3種,不過,近幾年對免疫療法 (尤其是免疫查核點抑制劑) 的興趣正逐漸高漲。2011年最初的免疫查核點抑制劑上市,現在有總合10億美元以上的銷售額。

本報告提供免疫查核點抑制劑相關臨床實驗最新趨勢相關分析,產業整體臨床實驗趨勢和近幾年主要的動向,各領域 (CTLA-4、PD-1、PDL-1等)的詳細資訊,臨床實驗的主要的促進、阻礙因素,最後階段的主要開發中產品,今後的市場趨勢預測的資訊彙整,為您概述為以下內容。

目錄

  • 市場概要
  • 整體情形:開發中產品及臨床實驗分析
  • CTLA-4 (細胞傷害性T淋巴球抗原4) 抑制劑:臨床實驗的進展
  • PD-1抑制劑:臨床實驗的進展
  • PDL-1抑制劑:臨床實驗的進展
  • 創新的免疫查核點抑制劑:臨床實驗的進展
  • 前臨床開發階段的分子
  • 分析對象的編入/除外標準
  • 推動及阻礙市場要素
  • 市場預測的前提條件
  • 市場趨勢的預測 (今後10年份)

圖表一覽

分析對象企業一覽 (共344家公司、團體)

目錄
Product Code: CT10006

Oncology market, for decades, has been pillared on three areas: Surgery, Radiation Therapy and Chemotherapy. Immuno-oncology, especially immune checkpoint inhibitors, has recently gained traction from several stakeholders. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. The drug is currently being mirrored by various other drugs such as Opdivo, Keytruda, Empliciti and Tecentriq in clinical development.

The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Most common forms of partnerships include clinical trial collaborations, product licensing agreements, acquisitions and research collaborations.

In addition to the marketed drugs, we expect a number of drugs currently in advanced stages of development to achieve blockbuster status in the near future. The anticipated success of immune checkpoint inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Synopsis

The primary objective of this report is to capture details on the various clinical trials that are currenly underway in the field of immune checkpoint inhibitors.We have identified a number of immune checkpoint inhibitors and clinical trials that are either being conducted or planned to be conducted for each of these drugs.

For each specific product, we have provided the following information:

  • Primary Drug
  • Highest Phase of Development
  • Manufacturer / Licensee
  • Target Receptor
  • Molecule Type
  • Route of Administration

For each specific trial, we have provided the following information:

  • 1. Indication
  • 2. Therapeutic Area
  • 3. Type of Cancer
  • 4. Sponsor/Collaborator
  • 5. Trial Title
  • 6. Trial Objective
  • 7. Trial Phase
  • 8. Trial Status
  • 9. Start Date
  • 10. End Date
  • 11. Enrolment
  • 12. Age Group
  • 13. Age Range
  • 14. Gender
  • 15. Inclusion Criteria
  • 16. Exclusion Criteria
  • 17. Study Type
  • 18. Study Design
  • 19. Primary Endpoints
  • 20. Secondary Endpoints
  • 21. Other Endpoints
  • 22. Treatment Arm(s)
  • 23. Location(s)
  • 24. Primary Trial Identifier
  • 25. Other Identifiers
  • 26. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

  • Drivers and Restraints of the specific drug classes (CTLA-4 inhibitors, PD-1 / PDL-1 inhibitors and novel immune checkpoint inhibitors), wherein we have presented our opinion on the drivers and challenges associated with each of the drug class type.
  • Sales forecast of the immune checkpoint inhibitors market over the course of next ten years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

Research Methodology

The data presented in this report has been gathered via secondary research. The prime secondary sources of information include

  • Clinical trial registries
  • Annual reports
  • Investor presentations
  • SEC filings
  • Company websites
  • Conference websites
  • Industry analysts' views

The focus has been on capturing the details on completed and ongoing clinical trials for immune checkpoint inhibitors. The report also provides an in-depth analysis of the competitive landscape for both pipeline molecules and clinical trials. The analysis is solely based on our knowledge and research gathered from various secondary sources of information.

Table of Contents

  • Introduction and Pipeline Details
  • 1. Market Overview
  • 2. Dashboard: Pipeline and Trial Analysis
  • 3. CTLA-4 Inhibitors: Trial Details
  • 4. PD-1 Inhibitors: Trial Details
  • 5. PDL-1 Inhibitors: Trial Details
  • 6. Novel Immune Checkpoint Inhibitors: Trial Details
  • 7. Molecules in Preclinical Development
  • 8. Inclusion / Exclusion Criteria
  • 9. Drivers and Restraints
  • 10. Market Forecast: Assumptions
  • 11. Market Forecast, 2016-2025

List of Figures

Pipeline and Trial Details

  • Figure 1 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Highest Phase of Development
  • Figure 2 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Target
  • Figure 3 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Phase of Development and Companies
  • Figure 4 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Type of Molecule
  • Figure 5 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Key Players
  • Figure 6 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Phase
  • Figure 7 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Status
  • Figure 8 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Sponsor Type
  • Figure 9 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Tumor Type
  • Figure 10 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Study Type
  • Figure 11 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Gender Type
  • Figure 12 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Molecule Type and Target
  • Figure 13 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Allocation Type
  • Figure 14 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Endpoint Classification
  • Figure 15 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Interventional Model
  • Figure 16 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Observational Model
  • Figure 17 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Masking
  • Figure 18 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Primary Purpose
  • Figure 19 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by Continent
  • Figure 20 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by G7 Countries
  • Figure 21 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by EU5 Countries
  • Figure 22 Immune Checkpoint Inhibitors in Preclinical Development: Distribution by Companies

Drivers and Restraints

  • Figure A: CTLA-4 Inhibitors: Drivers and Restraints
  • Figure B: PD-1 and PDL-1 Inhibitors: Drivers and Restraints
  • Figure C: Novel Immune Checkpoint Inhibitors: Drivers and Restraints

Market Forecast Analysis

  • Figure A: Immune Checkpoint Inhibitors Market Forecast, 2016-2025

List of Tables

Pipeline Analysis

  • Table A Companies Involved in the Development of Preclinical Immune Checkpoint Inhibitors

Pipeline Details

  • Table 1 CTLA-4 Inhibitors Clinical Development: Pipeline Details
  • Table 2 PD-1 Inhibitors Clinical Development: Pipeline Details
  • Table 3 PDL-1 Inhibitors Clinical Development: Pipeline Details
  • Table 4 Novel Immune Checkpoint Inhibitors Clinical Development: Pipeline Details
  • Table 5 Preclinical Development

Market Forecast Analysis

  • Table A Market Forecast: Assumptions

Listed Companies

The following companies and organisations have been mentioned in the report:

  • 1. Aarhus University Hospital
  • 2. Abbott
  • 3. AbbVie
  • 4. Academic and Community Cancer Research United
  • 5. Acerta Pharma BV
  • 6. Acetylon Pharmaceuticals
  • 7. ACT Oncology
  • 8. Adknoma Health Research
  • 9. AduroBioTech
  • 10. Advaxis
  • 11. Affimed
  • 12. Agenus
  • 13. AgonOx
  • 14. AHS Cancer Control Alberta
  • 15. AIO-Studien-gGmbH
  • 16. Alden Cancer Therapy II
  • 17. Alliance Foundation Trials
  • 18. Alligator Bioscience
  • 19. Altor Bioscience
  • 20. Ambrx
  • 21. American Association for Cancer Research
  • 22. Amgen
  • 23. Amplimmune
  • 24. AnaptysBio
  • 25. Apexigen
  • 26. arGEN-X
  • 27. ARMO BioSciences
  • 28. Astex Pharmaceuticals
  • 29. AstraZeneca
  • 30. Aurigene
  • 31. Australasian Lung Cancer Trials Group
  • 32. Australia and New Zealand Melanoma Trials Group
  • 33. Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  • 34. Avon Breast Cancer Foundation
  • 35. Azienda Ospedaliera Universitaria Senese
  • 36. Bank of Cyprus Oncology Centre
  • 37. Barbara Ann Karmanos Cancer Institute
  • 38. Bayer
  • 39. Baylor College of Medicine
  • 40. BeiGene
  • 41. BioInvent
  • 42. Bio-Matrix Scientific Group
  • 43. BioNovion
  • 44. Boston Biomedical
  • 45. Bristol-Myers Squibb
  • 46. Brown University
  • 47. California Pacific Medical Center Research Institute
  • 48. Calithera Biosciences
  • 49. Canadian Cancer Trials Group
  • 50. Cancer Prevention Research Institute of Texas
  • 51. Cancer Research Institute New York City
  • 52. Cancer Research UK
  • 53. Case Comprehensive Cancer Center
  • 54. Cedars-Sinai Medical Center
  • 55. Celgene
  • 56. Cell Genesys
  • 57. Celldex Therapeutics
  • 58. Cellerant Therapeutics
  • 59. Center for Cell and Gene Therapy Baylor College of Medicine
  • 60. Central and Eastern European Oncology Group
  • 61. Centre hospitalier de l'Université de Montréal
  • 62. Centre Hospitalier Universitaire de Nice
  • 63. Centre Hospitalier Universitaire Vaudois
  • 64. Checkmate Pharmaceuticals
  • 65. Checkpoint Therapeutics
  • 66. Children's Hospital Los Angeles
  • 67. City of Hope Medical Center
  • 68. Clinica Universidad de Navarra
  • 69. Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  • 70. Clovis Oncology
  • 71. Columbia University
  • 72. Comprehensive Cancer Center of Wake Forest University
  • 73. Comprehensive Cancer Centers of Nevada
  • 74. Compugen
  • 75. Copenhagen University Hospital at Herlev
  • 76. Corvus Pharmaceuticals
  • 77. Cure Brain Cancer Foundation
  • 78. CureTech
  • 79. Curis
  • 80. Dana-Farber Cancer Institute
  • 81. Delcath Systems
  • 82. Dendreon
  • 83. Department of Experimental Clinical Oncology
  • 84. Duke Cancer Institute
  • 85. Duke University
  • 86. Dutch Society of Physicians for Pulmonology and Tuberculosis
  • 87. Dynavax Technologies
  • 88. Earle A. Chiles Research Institute
  • 89. Eastern Cooperative Oncology Group
  • 90. Eddingpharm
  • 91. Eisai
  • 92. Eli Lilly and Company
  • 93. EMD Serono
  • 94. Emory University
  • 95. Enumeral
  • 96. EpicentRx
  • 97. European CanCer Organisation
  • 98. European Organisation for Research and Treatment of Cancer
  • 99. European Thoracic Oncology Platform
  • 100. Experimental Cancer Medicine Centre Network
  • 101. Facet Biotech
  • 102. Ferring Pharmaceuticals
  • 103. Five Prime Therapeutics
  • 104. Fondation ARC
  • 105. Fondazione IRCCS Istituto NazionaledeiTumori
  • 106. Fondazione Melanoma Onlus
  • 107. Fondazione Michelangelo
  • 108. Fox Chase Cancer Center
  • 109. Fred Hutchinson Cancer Research Center
  • 110. Frontier Science Foundation
  • 111. Galectin Therapeutics
  • 112. Gateway for Cancer Research
  • 113. Genentech
  • 114. Georgetown University
  • 115. Georgia Regents University
  • 116. German Breast Group
  • 117. GITR
  • 118. GlaxoSmithKline
  • 119. Gradalis
  • 120. Groupe Oncologie RadiotherapieTete et Cou
  • 121. Grupo Español Multidisciplinar de Melanoma
  • 122. H. Lee Moffitt Cancer Center and Research Institute
  • 123. Hackensack University Medical Center
  • 124. Hadassah Medical Organization
  • 125. Halozyme Therapeutics
  • 126. Haukeland University Hospital
  • 127. Heat Biologics
  • 128. Herlev Hospital
  • 129. High Impact Clinical Research Support Program
  • 130. Hoffmann-La Roche
  • 131. Honor Health Research Institute
  • 132. Hoosier Cancer Research Network
  • 133. Horizon Pharma Ireland
  • 134. Hospices Civils de Lyon
  • 135. Huntsman Cancer Institute
  • 136. HUYA Bioscience International
  • 137. Icahn School of Medicine at Mount Sinai
  • 138. Idera Pharmaceuticals
  • 139. Immune Design
  • 140. ImmuNext
  • 141. Immunocore
  • 142. ImmunoVaccine Technologies
  • 143. Immutep S.A.
  • 144. INC Research
  • 145. Incyte
  • 146. Infinity Pharmaceuticals
  • 147. Innate Pharma
  • 148. Institut Bergonié
  • 149. Institute of Cancer Research
  • 150. Instituto Nacional de Cancerologia de Mexico
  • 151. Intergroupe Francophone de CancerologieThoracique
  • 152. International Breast Cancer Study Group
  • 153. IOmet Pharma
  • 154. ISA Pharmaceuticals
  • 155. Istituto Scientifico Romagnolo per lo Studio e la curadei Tumori
  • 156. Italian Network for Tumor Biotherapy Foundation
  • 157. iTeos Therapeutics
  • 158. James Graham Brown Cancer Center
  • 159. Janssen Pharmaceuticals
  • 160. Jewish General Hospital
  • 161. Johns Hopkins University
  • 162. Jonsson Comprehensive Cancer Center
  • 163. Jounce Therapeutics
  • 164. JSS Medical Research
  • 165. Kadmon Corporation
  • 166. KAHR Medical
  • 167. Karyopharm Therapeutics
  • 168. Kids' Cancer Research Foundation
  • 169. King Faisal Specialist Hospital & Research Center
  • 170. Korean Cancer Study Group
  • 171. Kyowa Hakko Kirin Company
  • 172. Ludwig Institute for Cancer Research
  • 173. M.D. Anderson Cancer Center
  • 174. MacroGenics
  • 175. Mary Crowley Medical Research Center
  • 176. Massachusetts General Hospital
  • 177. Mayo Clinic
  • 178. Medarex
  • 179. Medical College of Wisconsin
  • 180. Medical Research Council
  • 181. Medical University of Vienna
  • 182. MedImmune
  • 183. Medivation
  • 184. Melanoma Institute Australia
  • 185. Melanoma Research Alliance
  • 186. Memgen
  • 187. Memorial Sloan Kettering Cancer Center
  • 188. Merck KGaA
  • 189. Merck Sharp & Dohme Corp.
  • 190. Millennium Pharmaceuticals
  • 191. Mologen AG
  • 192. Multimeric Biotherapeutics
  • 193. National Center for Tumor Diseases, Heidelberg
  • 194. National Health and Medical Research Council, Australia
  • 195. National Institute for Health Research, United Kingdom
  • 196. National Institute of Allergy and Infectious Diseases
  • 197. National Institutes of Health
  • 198. Nativis
  • 199. NCRI Clinical Studies Groups
  • 200. New Mexico Cancer Care Alliance
  • 201. New York University School of Medicine
  • 202. NewLink Genetics
  • 203. NHS Greater Glasgow and Clyde
  • 204. Northside Hospital
  • 205. Northwestern University
  • 206. Norwegian Cancer Society
  • 207. Norwegian Radium Hospital
  • 208. Novartis
  • 209. Ohio State University Comprehensive Cancer Center
  • 210. OHSU Knight Cancer Institute
  • 211. Oncolytics Biotech
  • 212. OncoMed Pharmaceuticals
  • 213. Oncothyreon
  • 214. Oncovir
  • 215. Ono Pharmaceutical
  • 216. Optimata
  • 217. Orega Biotech
  • 218. Oregon Health and Science University
  • 219. Oslo University Hospital
  • 220. Ozmosis Research
  • 221. Pelican Therapeutics
  • 222. Peloton Therapeutics
  • 223. Peregrine Pharmaceuticals
  • 224. Peter MacCallum Cancer Centre
  • 225. PETHEMA Foundation
  • 226. Pfizer
  • 227. Pharmaceutical Product Development
  • 228. Pharmacyclics
  • 229. Pieris Pharmaceuticals
  • 230. Plexxikon
  • 231. PRA Health Sciences
  • 232. Prima BioMed
  • 233. Prometheus Laboratories
  • 234. Prostate Oncology Specialists
  • 235. Provectus Pharmaceuticals
  • 236. Providence Cancer Center
  • 237. Providence Health & Services
  • 238. PsiOxus Therapeutics
  • 239. Quantum Leap Healthcare Collaborative
  • 240. Queen Mary University of London
  • 241. Queen's University, Belfast
  • 242. Quintiles
  • 243. Reata Pharmaceuticals
  • 244. Regeneron Pharmaceuticals
  • 245. Rhode Island Hospital
  • 246. Robert H. Lurie Cancer Center
  • 247. Roche / Genentech
  • 248. Roswell Park Cancer Institute
  • 249. Rouen University Hospital
  • 250. Royal Marsden NHS Foundation Trust
  • 251. RTOG Foundation
  • 252. Rutgers Cancer Institute of New Jersey
  • 253. Samsung Medical Center
  • 254. Sanford Health
  • 255. Sanofi
  • 256. Sarcoma Alliance for Research through Collaboration
  • 257. Seattle Genetics
  • 258. Seoul National University Hospital
  • 259. Servier
  • 260. SGS Aster-Cephac
  • 261. Sheba Medical Center
  • 262. Sidney Kimmel Comprehensive Cancer Center
  • 263. Solving Kids' Cancer
  • 264. Sorrento Therapeutics
  • 265. Southern Illinois University
  • 266. Southwest Oncology Group
  • 267. Spanish Lung Cancer Group
  • 268. St. Louis University
  • 269. Stand Up To Cancer
  • 270. Stanford University
  • 271. Sunnybrook Health Sciences Centre
  • 272. Swiss Group for Clinical Cancer Research
  • 273. Syndax Pharmaceuticals
  • 274. Takara Bio
  • 275. Tapimmune
  • 276. Tesaro
  • 277. TetraLogic Pharmaceuticals
  • 278. Texas Children's Hospital
  • 279. TG Therapeutics
  • 280. The EVAN Foundation
  • 281. The First People's Hospital of Changzhou
  • 282. The Leukemia and Lymphoma Society
  • 283. The Methodist Hospital System
  • 284. The Miriam Hospital
  • 285. The Netherlands Cancer Institute
  • 286. Theradex
  • 287. Theravectys
  • 288. Thomas Jefferson University
  • 289. ToleroTech
  • 290. Translational Genomics Research Institute
  • 291. Transplant Genomics
  • 292. U.S. Army Medical Research Acquisition Activity
  • 293. Ultimovacs
  • 294. Umanis
  • 295. UNC Lineberger Comprehensive Cancer Center
  • 296. UNICANCER
  • 297. United BioSource
  • 298. United States Department of Defense
  • 299. Universitair Ziekenhuis Brussel
  • 300. University College London
  • 301. University Health Network, Toronto
  • 302. University Hospital Dresden
  • 303. University Hospital Ghent
  • 304. University Hospital Heidelberg
  • 305. University Hospital Lille
  • 306. University Hospital Southampton NHS Foundation Trust
  • 307. University Hospital Tuebingen
  • 308. University Medical Center Groningen
  • 309. University of Birmingham
  • 310. University of California
  • 311. University of Chicago
  • 312. University of Colorado Denver
  • 313. University of Connecticut Health Center
  • 314. University of Edinburgh
  • 315. University of Glasgow
  • 316. University of Heidelberg Medical Center
  • 317. University of Leeds
  • 318. University of Leicester
  • 319. University of Louisville
  • 320. University of Manchester
  • 321. University of Michigan Cancer Center
  • 322. University of Minnesota
  • 323. University of Pennsylvania
  • 324. University of Pittsburgh
  • 325. University of Southampton
  • 326. University of Southern California
  • 327. University of Texas Southwestern Medical Center
  • 328. University of Utah
  • 329. University of Virginia
  • 330. University of Washington
  • 331. University of Wisconsin-Madison
  • 332. University of Zurich
  • 333. Vanderbilt University
  • 334. Vanderbilt-Ingram Cancer Center
  • 335. Vastra Gotaland Region
  • 336. VentiRx Pharmaceuticals
  • 337. Verastem
  • 338. Viralytics
  • 339. Vrije Universiteit Brussel
  • 340. VU University Medical Center
  • 341. Washington University School of Medicine
  • 342. West Japan Oncology Group
  • 343. Western Regional Medical Center
  • 344. Yale University
Back to Top